3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
10
Pain, Postoperative
9
Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Lung Neoplasms
8
Stomach Neoplasms
6
Colonic Neoplasms
6
Brain Neoplasms
6
Thyroid Neoplasms
5
Prostatic Neoplasms
5
Colorectal Neoplasms
5
Agnosia
4
Thromboembolism
3
Pain
3
Ovarian Neoplasms
3
Myofibroma
3
Head and Neck Neoplasms
3
Depression
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Supratentorial Neoplasms
2
Neoplasm Metastasis
2
Leiomyoma
2
Hemangioma
2
Arthritis, Rheumatoid
2
Vomiting
1
Visceral Pain
1
Uterine Cervical Neoplasms
1
Interventions
Carboplatin
41
Paclitaxel
40
pembrolizumab
38
Cyclophosphamide
23
Gemcitabine
22
130-nm albumin-bound paclitaxel
21
Doxorubicin
18
Cisplatin
18
Albumin-Bound Paclitaxel
18
atezolizumab
16
Taxes
15
Capecitabine
13
veliparib
10
Nivolumab
9
Docetaxel
9
Bevacizumab
9
olaparib
8
liposomal doxorubicin
7
Everolimus
7
spartalizumab
6
durvalumab
6
Epirubicin
6
trametinib
5
pegfilgrastim
5
eribulin
5
Irinotecan
5
Filgrastim
5
iniparib
4
binimetinib
4
apatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Triple Negative Breast Neoplasms
×
Saline Solution
×
Clear all
NCT04799249
2024-08-01
PRESERVE 2
G1 Therapeutics, Inc.
Phase 3
Completed
194 enrolled